TheraSphere With Durvalumab and Tremelimumab for HCC
TheraSphere With Durvalumab and Tremelimumab for HCC
Active, not recruiting · NCT05063565 · Registry updated 2026-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TheraSphere With Durvalumab and Tremelimumab for HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-10-01 | NCT05063565 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Biocompatibles UK Ltd | 2 |
| Boston Scientific Corporation | 148 |
35 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.